[Methotrexate-related lymphomatoid granulomatosis in a patient with rheumatoid arthritis]. 2011

Megumi Inaba, and Sunao Ushijim, and Naomi Hirata, and Tetsushi Saisyoji, and Mitsuhiko Kitaoka, and Takeshi Yoshinaga
Department of Respiratory Medicine, Kumamoto Chuo Hospital.

A 76-year-old man who was taking prednisolone and methotrexate for rheumatoid arthritis presented with gastric ulcers. Chest X-ray images showed multiple pulmonary nodules. Transbronchial lung biopsy specimens showed lymphocytic infiltrates but no malignant cells. The radiographic findings gradually ameliorated over a month, but then deteriorated 5 months later. We performed video-assisted thoracoscopic biopsy of the left lung, and the biopsy specimens showed lymphocytic infiltration with necrosis, in which the atypical lymphocytes were positive for Epstein-Barr virus-encoded small RNAs in situ hybridization (EBER-ISH). A diagnosis of lymphomatoid granulomatosis was determined. One year before this diagnosis, the patient was found to have an inflammatory liver tumor that had disappeared spontaneously within a month. A new pathological review of the liver and stomach lesions demonstrated EBER-ISH-positive lymphocytes, and therefore we assumed that they were pathological features of lymphomatoid granulomatosis. The chest radiographic findings improved gradually after the discontinuation of methotrexate. We therefore suggest that methotrexate treatment may be associated with the development of lymphomatoid granulomatosis in patients with rheumatoid arthritis. Lymphoproliferative disorders, including lymphomatoid granulomatosis, should be considered in patients with rheumatoid arthritis who are receiving methotrexate.

UI MeSH Term Description Entries
D008230 Lymphomatoid Granulomatosis An angiocentric and angiodestructive lymphoproliferative disorder primarily involving the lungs. It is caused by an Epstein-Barr virus-induced transformation of the B-cells, in a T-cell rich environment. Clinically and pathologically it resembles EXTRANODAL NK-T-CELL LYMPHOMA. Granulomatosis, Lymphomatoid,Granulomatoses, Lymphomatoid,Lymphomatoid Granulomatoses
D008297 Male Males
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D001172 Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated. Rheumatoid Arthritis
D018501 Antirheumatic Agents Drugs that are used to treat RHEUMATOID ARTHRITIS. Anti-Rheumatic Agent,Anti-Rheumatic Drug,Antirheumatic Agent,Antirheumatic Disease-Modifying Second-Line Drug,Antirheumatic Drug,DMARD,Disease-Modifying Antirheumatic Drug,Disease-Modifying Antirheumatic Drugs,Anti-Rheumatic Agents,Anti-Rheumatic Agents, Non-Steroidal,Anti-Rheumatic Drugs,Antirheumatic Disease-Modifying Second-Line Drugs,Antirheumatic Drugs,Antirheumatic Drugs, Disease-Modifying,Disease-Modifying, Antirheumatic Second-Line Drugs,Agent, Anti-Rheumatic,Agent, Antirheumatic,Anti Rheumatic Agent,Anti Rheumatic Agents,Anti Rheumatic Agents, Non Steroidal,Anti Rheumatic Drug,Anti Rheumatic Drugs,Antirheumatic Disease Modifying Second Line Drug,Antirheumatic Disease Modifying Second Line Drugs,Antirheumatic Drug, Disease-Modifying,Antirheumatic Drugs, Disease Modifying,Disease Modifying Antirheumatic Drug,Disease Modifying Antirheumatic Drugs,Disease Modifying, Antirheumatic Second Line Drugs,Drug, Anti-Rheumatic,Drug, Antirheumatic,Drug, Disease-Modifying Antirheumatic,Non-Steroidal Anti-Rheumatic Agents

Related Publications

Megumi Inaba, and Sunao Ushijim, and Naomi Hirata, and Tetsushi Saisyoji, and Mitsuhiko Kitaoka, and Takeshi Yoshinaga
January 2014, Minerva anestesiologica,
Megumi Inaba, and Sunao Ushijim, and Naomi Hirata, and Tetsushi Saisyoji, and Mitsuhiko Kitaoka, and Takeshi Yoshinaga
January 2014, Internal medicine (Tokyo, Japan),
Megumi Inaba, and Sunao Ushijim, and Naomi Hirata, and Tetsushi Saisyoji, and Mitsuhiko Kitaoka, and Takeshi Yoshinaga
September 2007, Clinical rheumatology,
Megumi Inaba, and Sunao Ushijim, and Naomi Hirata, and Tetsushi Saisyoji, and Mitsuhiko Kitaoka, and Takeshi Yoshinaga
July 2009, Onkologie,
Megumi Inaba, and Sunao Ushijim, and Naomi Hirata, and Tetsushi Saisyoji, and Mitsuhiko Kitaoka, and Takeshi Yoshinaga
July 2023, Internal medicine (Tokyo, Japan),
Megumi Inaba, and Sunao Ushijim, and Naomi Hirata, and Tetsushi Saisyoji, and Mitsuhiko Kitaoka, and Takeshi Yoshinaga
January 2007, Scandinavian journal of rheumatology,
Megumi Inaba, and Sunao Ushijim, and Naomi Hirata, and Tetsushi Saisyoji, and Mitsuhiko Kitaoka, and Takeshi Yoshinaga
October 2019, Internal medicine (Tokyo, Japan),
Megumi Inaba, and Sunao Ushijim, and Naomi Hirata, and Tetsushi Saisyoji, and Mitsuhiko Kitaoka, and Takeshi Yoshinaga
January 2015, Internal medicine (Tokyo, Japan),
Megumi Inaba, and Sunao Ushijim, and Naomi Hirata, and Tetsushi Saisyoji, and Mitsuhiko Kitaoka, and Takeshi Yoshinaga
March 2014, [Rinsho ketsueki] The Japanese journal of clinical hematology,
Megumi Inaba, and Sunao Ushijim, and Naomi Hirata, and Tetsushi Saisyoji, and Mitsuhiko Kitaoka, and Takeshi Yoshinaga
February 1994, Likars'ka sprava,
Copied contents to your clipboard!